FR13C0044I1 - - Google Patents
Info
- Publication number
- FR13C0044I1 FR13C0044I1 FR13C0044C FR13C0044I1 FR 13C0044 I1 FR13C0044 I1 FR 13C0044I1 FR 13C0044 C FR13C0044 C FR 13C0044C FR 13C0044 I1 FR13C0044 I1 FR 13C0044I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41759002P | 2002-10-10 | 2002-10-10 | |
| PCT/EP2003/011212 WO2004032938A1 (en) | 2002-10-10 | 2003-10-09 | Use of dihydroimidazolones for the treatment of epilepsy in dogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR13C0044I1 true FR13C0044I1 (ja) | 2013-08-30 |
| FR13C0044I2 FR13C0044I2 (fr) | 2014-03-07 |
Family
ID=32094042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR13C0044C Active FR13C0044I2 (fr) | 2002-10-10 | 2013-07-24 | Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine |
| FR22C1033C Active FR22C1033I1 (fr) | 2002-10-10 | 2022-06-30 | Utilisation de dihydroimidazolones pour le traitement des chiens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR22C1033C Active FR22C1033I1 (fr) | 2002-10-10 | 2022-06-30 | Utilisation de dihydroimidazolones pour le traitement des chiens |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20050070537A1 (ja) |
| EP (3) | EP1553952B1 (ja) |
| JP (4) | JP4694202B2 (ja) |
| KR (2) | KR20110063843A (ja) |
| CN (2) | CN1726040B (ja) |
| AR (1) | AR041573A1 (ja) |
| AT (1) | ATE418337T1 (ja) |
| AU (2) | AU2003273978B2 (ja) |
| BE (1) | BE2013C046I2 (ja) |
| BR (1) | BR0315225A (ja) |
| CA (2) | CA2501772C (ja) |
| CY (3) | CY1109961T1 (ja) |
| DE (1) | DE60325496D1 (ja) |
| DK (2) | DK2845594T3 (ja) |
| ES (2) | ES2316808T3 (ja) |
| FR (2) | FR13C0044I2 (ja) |
| HK (1) | HK1085920A1 (ja) |
| HR (3) | HRP20090667B1 (ja) |
| HU (2) | HUS1300035I1 (ja) |
| LU (1) | LU92238I2 (ja) |
| MX (1) | MXPA05003663A (ja) |
| NZ (1) | NZ539864A (ja) |
| PL (2) | PL238776B1 (ja) |
| PT (2) | PT2845594T (ja) |
| SI (2) | SI1553952T1 (ja) |
| TW (2) | TWI424849B (ja) |
| WO (1) | WO2004032938A1 (ja) |
| ZA (1) | ZA200502245B (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
| MXPA05013196A (es) * | 2003-07-11 | 2006-03-09 | Elbion Ag | Metodo para tratar o evitar trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa 3 del receptor de benzodiazepina. |
| JP2014521714A (ja) | 2011-08-12 | 2014-08-28 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネコ科動物の心不全を治療および予防する方法において使用するための奇異性電流（Ｉｆ）阻害薬 |
| JP6193613B2 (ja) * | 2013-05-10 | 2017-09-06 | 学校法人麻布獣医学園 | てんかん発作のモニタリングシステム及びモニタリング方法 |
| US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
| US9856250B2 (en) | 2014-05-28 | 2018-01-02 | Toa Eiyo Ltd. | Substituted tropane derivatives |
| WO2016044370A1 (en) | 2014-09-16 | 2016-03-24 | India Globalization Capital, Inc. | Cannabinoid composition and method for treating pain |
| CA2974895A1 (en) | 2015-01-25 | 2016-07-28 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
| WO2017027651A1 (en) | 2015-08-12 | 2017-02-16 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
| EP3471746A4 (en) | 2016-06-15 | 2020-02-26 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR TREATING EPILEPTIC DISORDERS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044021A (en) | 1971-10-21 | 1977-08-23 | American Cyanamid Company | Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism |
| US3932452A (en) | 1975-02-07 | 1976-01-13 | Morton-Norwich Products, Inc. | 1-Arylmethyl-2-imidazolidinones |
| US5869481A (en) | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
| DE19532668A1 (de) * | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
| DE19721580A1 (de) * | 1997-05-23 | 1998-11-26 | Dresden Arzneimittel | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
| JP2002507211A (ja) * | 1997-06-26 | 2002-03-05 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ジヒドロホノキオール組成物の合成 |
| JP4669095B2 (ja) | 1999-07-19 | 2011-04-13 | 太陽化学株式会社 | ペットの問題行動抑制組成物 |
| PL210862B1 (pl) | 2002-03-07 | 2012-03-30 | Boehringer Ingelheim Pharma | Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji |
| US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| JP2014521714A (ja) | 2011-08-12 | 2014-08-28 | ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネコ科動物の心不全を治療および予防する方法において使用するための奇異性電流（Ｉｆ）阻害薬 |
| US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
-
2003
- 2003-10-06 US US10/680,459 patent/US20050070537A1/en not_active Abandoned
- 2003-10-08 TW TW098142077A patent/TWI424849B/zh not_active IP Right Cessation
- 2003-10-08 TW TW092127976A patent/TWI324067B/zh not_active IP Right Cessation
- 2003-10-09 BR BR0315225-1A patent/BR0315225A/pt active Pending
- 2003-10-09 SI SI200331504T patent/SI1553952T1/sl unknown
- 2003-10-09 NZ NZ539864A patent/NZ539864A/en not_active IP Right Cessation
- 2003-10-09 MX MXPA05003663A patent/MXPA05003663A/es active IP Right Grant
- 2003-10-09 JP JP2004542480A patent/JP4694202B2/ja not_active Expired - Lifetime
- 2003-10-09 PT PT141910844T patent/PT2845594T/pt unknown
- 2003-10-09 ES ES03757945T patent/ES2316808T3/es not_active Expired - Lifetime
- 2003-10-09 CN CN2003801057558A patent/CN1726040B/zh not_active Expired - Lifetime
- 2003-10-09 DE DE60325496T patent/DE60325496D1/de not_active Expired - Lifetime
- 2003-10-09 CA CA2501772A patent/CA2501772C/en not_active Expired - Lifetime
- 2003-10-09 DK DK14191084.4T patent/DK2845594T3/da active
- 2003-10-09 KR KR1020117009632A patent/KR20110063843A/ko not_active Application Discontinuation
- 2003-10-09 PL PL397320A patent/PL238776B1/pl unknown
- 2003-10-09 ES ES14191084T patent/ES2908453T3/es not_active Expired - Lifetime
- 2003-10-09 DK DK03757945T patent/DK1553952T3/da active
- 2003-10-09 PT PT03757945T patent/PT1553952E/pt unknown
- 2003-10-09 CN CN2010101440231A patent/CN101890019A/zh active Pending
- 2003-10-09 SI SI200332622T patent/SI2845594T1/sl unknown
- 2003-10-09 PL PL374603A patent/PL214702B1/pl unknown
- 2003-10-09 AR ARP030103685A patent/AR041573A1/es unknown
- 2003-10-09 EP EP03757945A patent/EP1553952B1/en not_active Expired - Lifetime
- 2003-10-09 CA CA2727722A patent/CA2727722C/en not_active Expired - Lifetime
- 2003-10-09 KR KR1020057006150A patent/KR101110587B1/ko active Protection Beyond IP Right Term
- 2003-10-09 EP EP08167818A patent/EP2036563A1/en not_active Ceased
- 2003-10-09 HR HRP20090667AA patent/HRP20090667B1/hr not_active IP Right Cessation
- 2003-10-09 EP EP14191084.4A patent/EP2845594B1/en not_active Expired - Lifetime
- 2003-10-09 WO PCT/EP2003/011212 patent/WO2004032938A1/en active Application Filing
- 2003-10-09 AT AT03757945T patent/ATE418337T1/de active
- 2003-10-09 AU AU2003273978A patent/AU2003273978B2/en not_active Expired
-
2005
- 2005-03-17 ZA ZA2005/02245A patent/ZA200502245B/en unknown
- 2005-04-08 HR HRP20050322AA patent/HRP20050322B1/hr not_active IP Right Cessation
-
2006
- 2006-05-23 HK HK06105907.5A patent/HK1085920A1/xx not_active IP Right Cessation
-
2007
- 2007-07-18 US US11/879,708 patent/US8859540B2/en active Active
-
2009
- 2009-03-20 CY CY20091100314T patent/CY1109961T1/el unknown
- 2009-10-12 AU AU2009225322A patent/AU2009225322A1/en not_active Abandoned
-
2010
- 2010-12-28 JP JP2010293113A patent/JP2011068685A/ja not_active Withdrawn
-
2012
- 2012-09-14 US US13/616,440 patent/US8962617B2/en not_active Expired - Lifetime
-
2013
- 2013-07-03 LU LU92238C patent/LU92238I2/fr unknown
- 2013-07-03 BE BE2013C046C patent/BE2013C046I2/fr unknown
- 2013-07-11 CY CY2013031C patent/CY2013031I1/el unknown
- 2013-07-24 FR FR13C0044C patent/FR13C0044I2/fr active Active
- 2013-07-24 HU HUS1300035C patent/HUS1300035I1/hu unknown
-
2014
- 2014-02-14 JP JP2014026704A patent/JP6249812B2/ja not_active Expired - Lifetime
- 2014-11-17 US US14/542,888 patent/US9469611B2/en not_active Expired - Lifetime
-
2016
- 2016-02-29 JP JP2016038151A patent/JP2016104817A/ja not_active Withdrawn
- 2016-08-30 US US15/251,022 patent/US20160367562A1/en not_active Abandoned
-
2020
- 2020-02-07 HR HRP20200207AA patent/HRP20200207A2/hr not_active Application Discontinuation
-
2022
- 2022-03-31 CY CY20221100250T patent/CY1125103T1/el unknown
- 2022-06-30 FR FR22C1033C patent/FR22C1033I1/fr active Active
- 2022-07-28 HU HUS2200036C patent/HUS2200036I1/hu unknown